NCT06691165 Improving 24-hour Blood Pressure Stability in Spinal Cord Injury With Low Oxygen Therapy
| NCT ID | NCT06691165 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | Glen Foster |
| Condition | Spinal Cord Injury |
| Study Type | INTERVENTIONAL |
| Enrollment | 10 participants |
| Start Date | 2025-10-23 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 10 participants in total. It began in 2025-10-23 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study examines the effects of low oxygen therapy (LOT) on the stability of 24-hour blood pressure in persons with chronic cervical spinal cord injury. This study will examine if brief episodes of breathing lower oxygen, termed low oxygen therapy (LOT), which has been shown to enhance autonomic nervous system activity, can improve blood pressure stability in individuals with spinal cord injury. The research team will assess 24-hour blood pressure, as well as cardiac, vascular, and autonomic function before and after a 4-day LOT treatment intervention. This study will advance current understanding of treatments to mitigate cardiovascular disease risk in people with spinal cord injuries.
Eligibility Criteria
Inclusion Criteria: * Are between the ages of 19-65 * Living with a chronic cervical (at or above T1) spinal cord injury of at least one year * Are fluent in english Exclusion Criteria: * High-cervical injuries requiring ventilator assistance to breathe will be excluded on account of the necessity of the facemask for the delivery of hypoxia * Unhealed fracture, contracture, or pressure sore that might interfere with participants' ability to complete the protocol * Additional concurrent neurological conditions (e.g., multiple sclerosis, Parkinson disease, stroke or brain injury) * Uncontrolled cardiovascular or pulmonary disease * Severe neuropathic pain * Severe recurrent autonomic dysreflexia * History of seizure disorders * Known pregnancy
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06691165 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, up to 65 Years, studying Spinal Cord Injury. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06691165 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06691165 currently recruiting?
Yes, NCT06691165 is actively recruiting participants. Contact the research team at sthrall@student.ubc.ca for enrollment information.
Where is the NCT06691165 trial being conducted?
This trial is being conducted at Kelowna, Canada, Vancouver, Canada.
Who is sponsoring the NCT06691165 clinical trial?
NCT06691165 is sponsored by Glen Foster. The trial plans to enroll 10 participants.